Bristol Myers Squibb ends development of Orum Therapeutics' ORM-6151 after early trial review
Bristol Myers Squibb has stopped work on ORM-6151, a degrader-antibody conjugate from Orum Therapeutics, after reviewing Phase I trial data.
Milestone payment 2 articles
A milestone payment is contingent consideration that becomes payable when a contractually defined development, regulatory, commercial or sales event is achieved. Biotechnology licensing and partnership agreements often use milestones to distribute economic value over the life of an asset rather than paying the entire amount upfront. Milestones differ from royalties because they are event-triggered, generally nonrecurring payments, while royalties are usually linked to product sales over a defined period.
Roche signs $1B discovery deal for Dualitas bispecific antibody platform
Dualitas Therapeutics has signed a $36.5 million upfront agreement with Roche for access to its DualScreen Bispecific Discovery Engine, with total payments that could reach $1 billion.